Literature DB >> 15108075

Prognostic factors of anaplastic thyroid carcinoma.

Minoru Kihara1, Akira Miyauchi, Akira Yamauchi, Hiroyasu Yokomise.   

Abstract

PURPOSE: Anaplastic thyroid carcinoma (ATC) is a relatively rare but very aggressive malignancy, which usually results in death a few months after diagnosis. However, some patients survive for a long time, and the purpose of this study was to identify the prognostic factors of ATC.
METHODS: We retrospectively analyzed the records of 19 patients diagnosed with ATC in our institution between 1984 and 2002.
RESULTS: The median survival was 9.4 months, with a range of 0.6-76.3 months, and the 1-, 2-, and 5-year survival rates were 21%, 11%, and 5%, respectively. The mean tumor size was 5.7 cm, with a range of 3.6-10.5 cm, and complete resection was achieved in 4 patients. The prognostic factors according to univariate analysis were complete resection and small tumor size of less than 5 cm ( P = 0.005 and 0.047). However, according to multivariate analysis, complete resection was the only prognostic factor for ATC ( P = 0.015). No association was found between survival and acute symptoms, chemotherapy, radiation therapy, extrathyroidal invasion, distant metastasis, age, or leukocytosis.
CONCLUSION: At present, while there is no successful treatment regimen for ATC, only patients who undergo complete resection at a very early stage have any chance of long-term survival.

Entities:  

Mesh:

Year:  2004        PMID: 15108075     DOI: 10.1007/s00595-003-2737-6

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  24 in total

Review 1.  Thyroid and aging.

Authors:  Mouhammed Habra; Nicholas J Sarlis
Journal:  Rev Endocr Metab Disord       Date:  2005-05       Impact factor: 6.514

Review 2.  Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies.

Authors:  Eleonora Molinaro; Cristina Romei; Agnese Biagini; Elena Sabini; Laura Agate; Salvatore Mazzeo; Gabriele Materazzi; Stefano Sellari-Franceschini; Alessandro Ribechini; Liborio Torregrossa; Fulvio Basolo; Paolo Vitti; Rossella Elisei
Journal:  Nat Rev Endocrinol       Date:  2017-07-14       Impact factor: 43.330

3.  Anaplastic thyroid carcinoma: A comprehensive review of current and future therapeutic options.

Authors:  Francesco Perri; Giuseppe Di Lorenzo; Giuseppina Della Vittoria Scarpati; Carlo Buonerba
Journal:  World J Clin Oncol       Date:  2011-03-10

4.  Influence of risk grouping on therapeutic decisions in patients with anaplastic thyroid carcinoma.

Authors:  Chuanzheng Sun; Chao Li; Zedong Hu; Xiaojiang Li; Jiehua He; Ming Song; Guojun Li; Fenghua Zhang; Qiuli Li
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-04-10       Impact factor: 2.503

Review 5.  Management of anaplastic thyroid cancer.

Authors:  Xavier M Keutgen; Samira M Sadowski; Electron Kebebew
Journal:  Gland Surg       Date:  2015-02

Review 6.  Anaplastic thyroid carcinoma: pathogenesis and emerging therapies.

Authors:  R C Smallridge; J A Copland
Journal:  Clin Oncol (R Coll Radiol)       Date:  2010-04-24       Impact factor: 4.126

Review 7.  Anaplastic thyroid carcinoma: an overview.

Authors:  Wendy R Cornett; Anand K Sharma; Terry A Day; Mary S Richardson; Rana S Hoda; Jon A van Heerden; Jyotika K Fernandes
Journal:  Curr Oncol Rep       Date:  2007-03       Impact factor: 5.075

Review 8.  Surgical options in undifferentiated thyroid carcinoma.

Authors:  Brian Hung-Hin Lang; Chung-Yau Lo
Journal:  World J Surg       Date:  2007-05       Impact factor: 3.352

Review 9.  Treatment of patients with anaplastic thyroid cancer during the last 20 years: whether any progress has been made?

Authors:  Vesna Bisof; Zoran Rakusic; Marija Despot
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-06-03       Impact factor: 2.503

10.  Approach to the patient with anaplastic thyroid carcinoma.

Authors:  Robert C Smallridge
Journal:  J Clin Endocrinol Metab       Date:  2012-08       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.